-- 独立研究机构CFRA向提供了以下研究报告。CFRA分析师的观点总结如下： 汤森路透2026年第一季度调整后每股收益为1.23美元，高于去年同期的1.12美元，超出市场预期0.02美元；营收增长10%（有机增长8%），达到20.9亿美元，超出预期5000万美元。业绩超预期主要得益于三大业务板块的强劲增长，这三大板块增长11%（有机增长9%），占总营收的85%，展现了其在关键专业工作流程领域的强大实力。我们认为，CoCounsel等“受托级人工智能”产品的日益普及，以及经常性收入8%的有机增长，都为汤森路透稳健的订阅模式提供了有力支撑。管理层维持了2026年全年有机收入增长7.5%-8.0%和调整后EBITDA利润率提升100个基点的预期，但将净利息支出预期上调至1.8亿至1.9亿美元。我们预计人工智能在法律专业人士和企业业务板块的整合将持续保持增长势头，同时，3.32亿美元的强劲自由现金流（同比增长19%）和8.67亿美元的资本回报表明公司拥有强大的现金流生成能力和对股东友好的资金分配策略。
Related Articles
Australia
Citigroup Adjusts Price Target on Marathon Petroleum to $257 From $243, Maintains Neutral Rating
Marathon Petroleum (MPC) has an average rating of overweight and mean price target of $253.25, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $256.58, Change: $+4.04, Percent Change: +1.60%
$MPC
Research
Research Alert: Peg Reports Strong Q1 Beat; On Track For $4.2b Capex And 7% Eps Growth In 2026
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:PEG reported Q1 2026 adjusted EPS of $1.55 vs. $1.43 (+8.4% Y/Y, +8.5% vs. consensus), supported by higher PSE&G margins from regulated infrastructure investments and customer growth, partially offset by higher depreciation and interest expense. PSEG Power earnings increased due to higher realized power prices and lower O&M costs, offset by lower generation volumes. We see the company as on target for $4.2B full-year 2026 capex guidance after deploying ~$0.8B in Q1, while PEG maintained long-term targets including $24B-$28B total capex for 2026-2030 and a 6%-7.5% rate base CAGR. Management reaffirmed its 2026 EPS guidance of $4.28-$4.40, representing ~7% growth at the midpoint. Both residential electric and gas customers increased ~1% on a trailing-12-month basis, which we think reflects continued execution of the regulated investment program. Annualized dividends were increased ~6% to $2.68 for 2026. We view this as a competitive growth rate amongst Multi-Utility peers.
$PEG
Australia
Merck Completes Terns Pharmaceuticals Acquisition
Merck (MRK) said Tuesday it has completed the acquisition of Terns Pharmaceuticals after a cash tender offer at $53 per share.Terns' stock will no longer be listed on Nasdaq, it said.The deal will result in a charge to research and development expense of about $2.35 per share, included in Q2 and full year 2026 GAAP and non-GAAP results, Merck said.GAAP and non-GAAP EPS are also expected to take a hit of about $0.12 a share in 2026 on costs associated with advancing TERN-701 and costs of financing, it added.Price: $113.21, Change: $+0.10, Percent Change: +0.09%
$MRK$TERN